LON:IMM ImmuPharma (IMM) Share Price, News & Analysis GBX 2.06 +0.19 (+9.87%) As of 12:02 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock About ImmuPharma Stock (LON:IMM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ImmuPharma alerts:Sign Up Key Stats Today's Range 1.80▼ 2.0850-Day Range 1.95▼ 3.7052-Week Range 0.85▼ 7.40Volume1.30 million shsAverage Volume6.67 million shsMarket Capitalization£8.76 millionP/E RatioN/ADividend Yield0.77%Price TargetN/AConsensus RatingN/A Company Overview ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. Read More Receive IMM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmuPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address IMM Stock News HeadlinesImmuPharma celebrates "significant milestone" for P140 platformMarch 14, 2025 | lse.co.ukImmuPharma addresses recent share price volatilityJanuary 28, 2025 | msn.comCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring. July 16 at 2:00 AM | Timothy Sykes (Ad)We Think ImmuPharma (LON:IMM) Needs To Drive Business Growth CarefullyJanuary 25, 2025 | finance.yahoo.comImmuPharma PLC (25I.MU)January 18, 2025 | ca.finance.yahoo.comSMALL CAP MOVERS: ImmuPharma lifted by groundbreaking researchJanuary 10, 2025 | msn.comAIM WINNERS & LOSERS: ImmuPharma jumps; Impax Asset hit by outflowsJanuary 9, 2025 | lse.co.ukImmuPharma Targets Global Partnerships at Key Biotech EventsJanuary 9, 2025 | markets.businessinsider.comSee More Headlines IMM Stock Analysis - Frequently Asked Questions How have IMM shares performed this year? ImmuPharma's stock was trading at GBX 1.18 at the start of the year. Since then, IMM shares have increased by 74.9% and is now trading at GBX 2.06. How were ImmuPharma's earnings last quarter? ImmuPharma plc (LON:IMM) issued its quarterly earnings data on Monday, May, 19th. The company reported ($0.60) earnings per share for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative trailing twelve-month return on equity of 131.41%. How do I buy shares of ImmuPharma? Shares of IMM stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of ImmuPharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmuPharma investors own include Castleton Technology (CTP), 4D pharma (DDDD), Motif Bio (MTFB), Thor Energy (THR), Aminex (AEX) and GSK (GSK). Company Calendar Last Earnings5/19/2025Today7/16/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:IMM CIKN/A Webwww.immupharma.org Phone+44-20-71524080FaxN/AEmployees13Year FoundedN/AProfitability EPS (Trailing Twelve Months)GBX (0.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£2.51 million Net Margins3,519.56% Pretax MarginN/A Return on Equity-131.41% Return on Assets-43.00% Debt Debt-to-Equity RatioN/A Current Ratio1.60 Quick Ratio1.03 Sales & Book Value Annual Sales-£71.31 thousand Price / Sales-122.80 Cash FlowGBX 0.10 per share Price / Cash Flow20.50 Book ValueGBX 0.65 per share Price / Book3.19Miscellaneous Outstanding Shares425,094,500Free FloatN/AMarket Cap£8.76 million OptionableNot Optionable Beta1.53 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:IMM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored[ATTENTION] This Crypto Rocket Is About Launch…Every crypto bull market ends with a final surge — the window where fortunes are made fast. According to tw...Crypto Swap Profits | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmuPharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmuPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.